Figure 2
Figure 2. Targeting MUC1-C downregulates β-catenin. (A-B) The WT and CRISPR RPMI8226 (A) and U266 (B) cells were subjected to immunoblot analysis with the indicated antibodies. (C-D) RPMI8226 (C) and U266 (D) cells were treated with 5 μM CP-2 or GO-203 for 48 hours. Lysates were immunoblotted with the indicated antibodies. (E-F) RPMI8226 (E) and U266 (F) cells were treated with control vehicle (DMSO) or 10 μM JW67 for 48 hours. The cells were analyzed for MYC mRNA levels by qRT-PCR (left). The results (mean ± SD of 3 determinations) are expressed as relative MYC mRNA levels as compared with that obtained for the control cells (assigned a value of 1). Lysates from the control (DMSO) and JW67-treated cells were immunoblotted with the indicated antibodies (right).

Targeting MUC1-C downregulates β-catenin. (A-B) The WT and CRISPR RPMI8226 (A) and U266 (B) cells were subjected to immunoblot analysis with the indicated antibodies. (C-D) RPMI8226 (C) and U266 (D) cells were treated with 5 μM CP-2 or GO-203 for 48 hours. Lysates were immunoblotted with the indicated antibodies. (E-F) RPMI8226 (E) and U266 (F) cells were treated with control vehicle (DMSO) or 10 μM JW67 for 48 hours. The cells were analyzed for MYC mRNA levels by qRT-PCR (left). The results (mean ± SD of 3 determinations) are expressed as relative MYC mRNA levels as compared with that obtained for the control cells (assigned a value of 1). Lysates from the control (DMSO) and JW67-treated cells were immunoblotted with the indicated antibodies (right).

Close Modal

or Create an Account

Close Modal
Close Modal